Y
Yok-Lam Kwong
Researcher at University of Hong Kong
Publications - 444
Citations - 17258
Yok-Lam Kwong is an academic researcher from University of Hong Kong. The author has contributed to research in topics: Lymphoma & Leukemia. The author has an hindex of 62, co-authored 411 publications receiving 15094 citations. Previous affiliations of Yok-Lam Kwong include Queen Mary Hospital & Queen Mary University of London.
Papers
More filters
Journal ArticleDOI
Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation
TL;DR: There was improvement in symptoms, myocardial perfusion, and function at the ischaemic region on MRI after 3 months of follow-up, and future randomised, controlled studies are required to validate this initial encouraging result.
Journal ArticleDOI
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Anupama Reddy,Jenny Zhang,Nicholas S. Davis,Andrea B. Moffitt,Cassandra Love,Alexander Waldrop,Sirpa Leppä,Annika Pasanen,Leo Meriranta,Marja-Liisa Karjalainen-Lindsberg,Peter Nørgaard,Mette Merete Pedersen,Anne O. Gang,Estrid Høgdall,Tayla Heavican,Waseem Gul Lone,Javeed Iqbal,Qiu Qin,Guojie Li,So Young Kim,Jane Healy,Kristy L. Richards,Yuri Fedoriw,Leon Bernal-Mizrachi,Jean L. Koff,Ashley D. Staton,Christopher R. Flowers,Ora Paltiel,Neta Goldschmidt,Maria Calaminici,Andrew Clear,John G. Gribben,Evelyn T. Nguyen,Magdalena Czader,Sarah L. Ondrejka,Angela M. B. Collie,Eric D. Hsi,Eric Tse,Rex Au-Yeung,Yok-Lam Kwong,Gopesh Srivastava,William W.L. Choi,Andrew M. Evens,Monika Pilichowska,Manju Sengar,Nishitha Reddy,Shaoying Li,Amy Chadburn,Leo I. Gordon,Elaine S. Jaffe,Shawn Levy,Rachel E. Rempel,Tiffany Tzeng,Lanie Happ,Tushar Dave,Deepthi Rajagopalan,Jyotishka Datta,David B. Dunson,Sandeep S. Dave +58 more
TL;DR: An integrative analysis of whole-exome sequencing and transcriptome sequencing in a cohort of DLBCL patients is performed to comprehensively define the landscape of 150 genetic drivers of the disease and their functional roles to identify new therapeutic opportunities in the disease.
Journal ArticleDOI
Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
Motoko Yamaguchi,Yok-Lam Kwong,Won Seog Kim,Yoshinobu Maeda,Chizuko Hashimoto,Cheolwon Suh,Koji Izutsu,Fumihiro Ishida,Yasushi Isobe,Eisaburo Sueoka,Junji Suzumiya,Takao Kodama,Hiroshi Kimura,Rie Hyo,Shigeo Nakamura,Kazuo Oshimi,Kazuo Oshimi,Ritsuro Suzuki +17 more
TL;DR: SMILE chemotherapy is an effective treatment for newly diagnosed stage IV, relapsed or refractory ENKL and myelosuppression and infection during the treatment should be carefully managed.
Journal ArticleDOI
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
Chee Kin Hui,Winnie W.W. Cheung,Hai Ying Zhang,Wing Yan Au,Yui Hung Yueng,Anskar Y.H. Leung,Nancy Leung,John M. Luk,Albert K. W. Lie,Yok-Lam Kwong,Raymond Liang,George K. K. Lau +11 more
TL;DR: Close surveillance for a 100-fold increase in HBV DNA is recommended for HBsAg-negative patients treated with chemotherapy so that early commencement of antiviral therapy can be initiated before the occurrence of de novo HBV-related hepatitis.
Journal ArticleDOI
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase
Yok-Lam Kwong,Thomas S. Y. Chan,Daryl Tan,Seok Jin Kim,Li-Mei Poon,Benjamin Mow,Pek-Lan Khong,Florence Loong,Rex Au-Yeung,Jabed Iqbal,Colin Phipps,Eric Tse +11 more
TL;DR: PD1 blockade with pembrolizumab was a potent strategy for NK/T-cell lymphomas failing l-asparaginase regimens and five CR patients were still in remission, the only adverse event was grade 2 skin graft-versus-host disease in one patient with previous allogeneic HSCT.